| Ad Title: |
Early Stage Ovarian Cancer |
| Study Title: |
GOG 175: Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Every 21 Days for 3 Courses Plus Weekly Low Dose Paclitaxel 40 mg/m2/week Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Every 21 Days for 3 Courses Plus Observation in Patients with Early Stage Ovarian Carcinoma |
| Protocol Number: |
1198-45000 |
| Department(s) involved in the Study: |
Obstetrics & Gynecology, Simmons Comprehensive Cancer Center
|
| Purpose of the Study: |
To determine whether low-dose intravenous paclitaxel, after standard treatment, can prevent or slow the recurrence of ovarian cancer. |
| Participant Eligibility: |
1. Patients must have a diagnosis of epithelial ovarian cancer.
2. Patients may have received no prior treatment for this malignancy except surgical therapy. |
| Disease/Condition Under Study: |
Early Stage Ovarian Cancer |
| Cancer Related Study: |
Yes
|
| Study Drug(s): |
|
| Study Device(s): |
|
| Study Doctor: |
Dr. David Miller |
| Location of Study: |
|
Sites
|
Recruiting at this Site
|
|
Parkland Memorial Hospital
|
Yes
|
|
UT Southwestern University Hospitals Zale Lipshy Building
|
Yes
|
|
Aston Ambulatory Care Center
|
Yes
|
|
| Contact Phone: |
214_648_6753 |
| Email: |
Paula.Honea@utsouthwestern.edu |
| Other Information: |
This is a National Cancer Institute and Gynecologic Oncology Group sponsored trial. |
| Website Keywords: |
Gyn Oncology, Gynecology, Women's Health
|
| Medical Keywords: |
cancer
|
